44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
Titel:
44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
Auteur:
Colombo, N. Coleman, R.L. Wu, X. Kose, F. Wenham, R. Sebastianelli, A. Hasegawa, K. Zsiros, E. De La Motte Rouge, T. Bidzinski, M. McNeish, I. Sehouli, J. Korach, J. Debruyne, P.R. Kim, J-W. De Melo, A.C. Peng, X. Bogusz, A.M. Yamada, K. Monk, B.J.